Conjupri Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Levamlodipine maleate

Indications/Uses

1st-line treatment of HTN. Monotherapy to control BP. In combination w/ thiazide diuretic, α-blockers, β-adrenoceptor blockers or ACE inhibitors in patients inadequately controlled on a single antihypertensive agent.

Dosage/Direction for Use

Initially 2.5 mg once daily. Max: 5 mg once daily.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity to levamlodipine maleate, dihydropyridines or any of the inert ingredients.

MIMS Class

Calcium Antagonists

ATC Classification

C08CA17 - levamlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.

Regulatory Classification

POM

Presentation/Packing

Form

Conjupri tab 2.5 mg

Packing/Price

1's

Form

Conjupri tab 5 mg

Packing/Price

1's

Conjupri

levamlodipine

Manufacturer:

CSPC Ouyi Pharmaceutical